Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2021-04-12 , DOI: 10.1002/ejhf.2191
Karola S Jering ₁ , Brian Claggett ₁ , Marc A Pfeffer ₁ , Christopher Granger ₂ , Lars Køber ₃ , Eldrin F Lewis ₄ , Aldo P Maggioni ₅ , Douglas Mann ₆ , John J V McMurray ₇ , Jean-Lucien Rouleau ₈ , Scott D Solomon ₁ , Philippe G Steg ₉ , Peter van der Meer ₁₀ , Margaret Wernsing ₁₁ , Katherine Carter ₁₁ , Weinong Guo ₁₁ , Yinong Zhou ₁₁ , Martin Lefkowitz ₁₁ , Jianjian Gong ₁₁ , Yi Wang ₁₁ , Bela Merkely ₁₂ , Stella M Macin ₁₃ , Urmil Shah ₁₄ , Jose C Nicolau ₁₅ , Eugene Braunwald ₁₆

Affiliation

Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Duke University Medical Center, Durham, NC, USA.
Rigshospitalet, Copenhagen, Denmark.
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA.
ANMCO Research Center, Florence, Italy.
Washington University Medical Center, St Louis, MO, USA.
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Montreal Heart Institute, University of Montreal, Montreal, Canada.
Université de Paris, AP-HP (Assistance Publique-Hôpitaux de Paris), FACT (French Alliance for Cardiovascular Trials) and INSERM U-1148, Paris, France.
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Novartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Semmelweis University, Heart and Vascular Center, Budapest, Hungary.
Instituto de Cardiología JF Cabral Corrientes, Corrientes, Argentina.
Care Institute of Medical Sciences, Ahmedabad, India.
Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.

Patients surviving an acute myocardial infarction (AMI) are at risk of developing symptomatic heart failure (HF) or premature death. We hypothesized that sacubitril/valsartan, effective in the treatment of chronic HF, prevents development of HF and reduces cardiovascular death following high-risk AMI compared to a proven angiotensin-converting enzyme (ACE) inhibitor. This paper describes the study design and baseline characteristics of patients enrolled in the Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI) trial.

中文翻译：

前瞻性 ARNI 与 ACE 抑制剂试验以确定减少心肌梗塞 (PARADISE-MI) 后心力衰竭事件的优势：设计和基线特征

在急性心肌梗死 (AMI) 中幸存的患者有发生症状性心力衰竭 (HF) 或过早死亡的风险。我们假设与已证实的血管紧张素转换酶 (ACE) 抑制剂相比，沙库巴曲/缬沙坦在治疗慢性 HF 方面有效，可防止 HF 的发展并减少高危 AMI 后的心血管死亡。本文描述了参加前瞻性 ARNI 与 ACE 抑制剂试验的患者的研究设计和基线特征，以确定在减少心肌梗塞 (PARADISE-MI) 试验后心力衰竭事件方面的优势。

更新日期：2021-04-12

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南